T2 Biosystems (NASDAQ:TTOO – Get Free Report) announced its quarterly earnings results on Monday. The medical equipment provider reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.31, Yahoo Finance reports. The business had revenue of $1.95 million for the quarter. T2 Biosystems updated its FY 2024 guidance to EPS.
T2 Biosystems Stock Performance
Shares of T2 Biosystems stock traded up $0.03 during midday trading on Tuesday, reaching $4.77. The company had a trading volume of 143,821 shares, compared to its average volume of 272,518. The stock has a fifty day simple moving average of $5.12 and a 200 day simple moving average of $4.47. T2 Biosystems has a 1-year low of $2.60 and a 1-year high of $70.00.
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group raised their price objective on shares of T2 Biosystems from $3.00 to $5.00 and gave the stock a “hold” rating in a report on Tuesday.
About T2 Biosystems
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Read More
- Five stocks we like better than T2 Biosystems
- How to Evaluate a Stock Before BuyingÂ
- This Semiconductor Stock Is ON Track for a New High
- Why Invest in High-Yield Dividend Stocks?
- Why SoFi Stock is an Unmissable Growth Opportunity
- What Makes a Stock a Good Dividend Stock?
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
